Reduced density of hypothalamic VGF-immunoreactive neurons in schizophrenia: A potential link to impaired growth factor signaling and energy homeostasis

European Archives of Psychiatry and Clinical Neuroscience

Volumn 262, Issue 5, 2012, Pages 365-374

  Busse, Stefan ^a   Bernstein, Hans Gert ^a   Busse, Mandy ^b   Bielau, Hendrik ^a   Brisch, Ralf ^a   Mawrin, Christian ^a   Müller, Susan ^a   Zoltan Sarnyai ^c   Gos, Tomasz ^a,d   Bogerts, Bernhard ^a   Steiner, Johann ^a,e  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e PEMBROKE COLLEGE   (United Kingdom)

Author keywords

Granins; Histopathology; Hypothalamus; Postmortem; Schizophrenia; VGF

Indexed keywords

PEPTIDES AND PROTEINS; PROTEIN VGF; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIBODY LABELING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DENSITY; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENERGY BALANCE; HUMAN; HUMAN TISSUE; HYPOPHYSIS; HYPOTHALAMUS; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MORPHOMETRICS; NERVE CELL; NERVE FIBER; NEUROHYPOPHYSIS; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN TRANSPORT; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ADULT; AGED; ANALYSIS OF VARIANCE; CELL COUNT; FEMALE; HUMANS; HYPOTHALAMUS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEURONS; NEUROPEPTIDES; PITUITARY GLAND; POSTMORTEM CHANGES; SCHIZOPHRENIA;

EID: 84865002420     PISSN: 09401334     EISSN: 14338491     Source Type: Journal    
DOI: 10.1007/s00406-011-0282-7     Document Type: Article

References (41)

1. Alder J, Thakker-Varia S, Bangasser DA, Kuroiwa M, Plummer MR, Shors TJ, Black IB (2003) Brain-derived neurotrophic factor-induced gene expression reveals novel actions of vgf in hippocampal synaptic plasticity. J Neurosci 23:10800-10808 (Pubitemid 37499686)
2. APA (2000) Diagnostic and statistical manual of mental disorders, 4th revised edition (dsm-iv-tr). American Psychiatric Press, Washington, DC
3. Bartolomucci A, Pasinetti GM, Salton SR (2010) Granins as disease-biomarkers: translational potential for psychiatric and neurological disorders. Neuroscience 170:289-297
4. Bartolomucci A, Possenti R, Levi A, Pavone F, Moles A (2007) The role of the vgf gene and vgf-derived peptides in nutrition and metabolism. Genes Nutr 2:169-180
5. Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, Bogerts B (2010) The hypothalamus in schizophrenia research: No longer a wallflower existence. The Open Neuroendocrinol J 3:59-67
6. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P, Falkai P, Bogerts B (1998) Nitric oxide synthasecontaining neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83:867-875 (Pubitemid 28068907)
7. Brisch R, Bernstein HG, Dobrowolny H, Krell D, Stauch R, Trubner K, Steiner J, Ghabriel MN, Bielau H, Wolf R, Winter J, Kropf S, Gos T, Bogerts B (2011) A morphometric analysis of the septal nuclei in schizophrenia and affective disorders: reduced neuronal density in the lateral septal nucleus in bipolar disorder. Eur Arch Psychiatry Clin Neurosci 261:47-58
8. Cocco C, D'Amato F, Noli B, Ledda A, Brancia C, Bongioanni P, Ferri GL (2010) Distribution of vgf peptides in the human cortex and their selective changes in parkinson's and alzheimer's diseases. J Anat 217:683-693
9. Faludi G, Mirnics K (2011) Synaptic changes in the brain of subjects with schizophrenia. Int J Dev Neurosci 29:305-309
10. Ferri GL, Noli B, Brancia C, D'Amato F, Cocco C (2011) Vgf: An inducible gene product, precursor of a diverse array of neuroendocrine peptides and tissue-specific disease biomarkers. J Chem Neuroanat
11. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K, Someya T, Kakita A, Takahashi H, Nawa H (2002) Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenic patients. Mol Psychiatry 7:673-682 (Pubitemid 34984943)
12. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ (2011) Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol Psychiatry 16:960-972
13. Guest PC, Schwarz E, Krishnamurthy D, Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36:1092-1096
14. Guest PC, Wang L, Harris LW, Burling K, Levin Y, Ernst A, Wayland MT, Umrania Y, Herberth M, Koethe D, van Beveren NJ, Rothermundt M, McAllister G, Leweke FM, Steiner J, Bahn S (2010) Increased levels of circulating insulin-related peptides in first onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15:118-119
15. Hahm S, Fekete C, Mizuno TM, Windsor J, Yan H, Boozer CN, Lee C, Elmquist JK, Lechan RM, Mobbs CV, Salton SR (2002) Vgf is required for obesity induced by diet, gold thioglucose treatment, and agouti and is differentially regulated in pro-opiomelanocortin- and neuropeptide y-containing arcuate neurons in response to fasting. J Neurosci 22:6929-6938 (Pubitemid 35379151)
16. Hsu SM, Soban E (1982) Color modification of diaminobenzidine (dab) precipitation by metallic ions and its application for double immunohistochemistry. J Histochem Cytochem 30:1079-1082
17. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D, Gerth CW, Nolden BM, Gross S, Schreiber D, Reed B, Bahn S (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3:e428
18. Jethwa PH, Ebling FJ (2008) Role of vgf-derived peptides in the control of food intake, body weight and reproduction. Neuroendocrinology 88:80-87
19. Keilhoff G, Grecksch G, Bernstein HG, Roskoden T, Becker A (2010) Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 260:151-162
20. Levi A, Eldridge JD, Paterson BM (1985) Molecular cloning of a gene sequence regulated by nerve growth factor. Science 229:393-395 (Pubitemid 15073084)
21. Levi A, Ferri GL, Watson E, Possenti R, Salton SR (2004) Processing, distribution, and function of vgf, a neuronal and endocrine peptide precursor. Cell Mol Neurobiol 24:517-533 (Pubitemid 38988061)
22. Mai JK, Assheuer J, Paxinos G (2003) Atlas of the human brain. Academic Press, San Diego
23. Newcomer JW (2007) Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 68(4):8-13 (Pubitemid 46762118)
24. Reif A, Fritzen S, Finger M, Strobel A, Lauer M, Schmitt A, Lesch KP (2006) Neural stem cell proliferation is decreased in schizophrenia, but not in depression. Mol Psychiatry 11:514-522
25. Ruetschi U, Zetterberg H, Podust VN, Gottfries J, Li S, Hviid Simonsen A, McGuire J, Karlsson M, Rymo L, Davies H, Minthon L, Blennow K (2005) Identification of csf biomarkers for frontotemporal dementia using seldi-tof. Exp Neurol 196:273-281 (Pubitemid 41607815)
26. RyanMC,SharifiN,CondrenR, Thakore JH(2004) Evidence of basal pituitary-adrenal overactivity in first episode, drug naive patients with schizophrenia. Psychoneuroendocrinology 29:1065-1070 (Pubitemid 38833534)
27. Sivukhina EV, Jirikowski GF, Bernstein HG, Lewis JG, Herbert Z (2006) Expression of corticosteroid-binding protein in the human hypothalamus, co-localization with oxytocin and vasopressin. Horm Metab Res 38:253-259 (Pubitemid 43845218)
28. Snyder SE, Salton SR (1998) Expression of vgf mrna in the adult rat central nervous system. J Comp Neurol 394:91-105 (Pubitemid 28173263)
29. Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM, Bogerts B (2008) S100b-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 42:868-876 (Pubitemid 351787739)
30. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, Bogerts B (2006) Distribution of hla-dr-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 112:305-316 (Pubitemid 44275885)
31. Terwisscha van Scheltinga AF, Bakker SC, Kahn RS (2010) Fibroblast growth factors in schizophrenia. Schizophr Bull 36:1157-1166
32. Thakker-Varia S, Alder J (2009) Neuropeptides in depression: role of vgf. Behav Brain Res 197:262-278
33. Thakore JH (2004) Metabolic disturbance in first-episode schizophrenia. Br J Psychiatry Suppl 47:S76-S79 (Pubitemid 38482548)
34. Tirupati S, Chua LE (2007) Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders. Australas Psychiatry 15:470-473 (Pubitemid 350120843)
35. Trani E, Ciotti T, Rinaldi AM, Canu N, Ferri GL, Levi A, Possenti R (1995) Tissue-specific processing of the neuroendocrine protein vgf. J Neurochem 65:2441-2449
36. van den Pol AN, Decavel C, Levi A, Paterson B (1989) Hypothalamic expression of a novel gene product, vgf: Immunocytochemical analysis. J Neurosci 9:4122-4137. (Pubitemid 20027233)
37. Vargas HE, Gama CS, Andreazza AC, Medeiros D, Stertz L, Fries G, Palha J, Cereser KM, Berk M, Kapczinski F, Belmontede- Abreu PS (2008) Decreased serum neurotrophin 3 in chronically medicated schizophrenic males. Neurosci Lett 440:197-201
38. Watson E, Fargali S, Okamoto H, Sadahiro M, Gordon RE, Chakraborty T, Sleeman MW, Salton SR (2009) Analysis of knockout mice suggests a role for vgf in the control of fat storage and energy expenditure. BMC Physiol 9:19
39. Yazici MK, Anil Yagcioglu AE, Ertugrul A, Eni N, Karahan S, Karaagaoglu E, Tokgozoglu SL (2011) The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in turkey. Eur Arch Psychiatry Clin Neurosci 261:69-78
40. Zhao Z, Lange DJ, Ho L, Bonini S, Shao B, Salton SR, Thomas S, Pasinetti GM (2008) Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (als), with a potential role in disease pathogenesis. Int J Med Sci 5:92-99 (Pubitemid 351880757)
41. Zubin J, Spring B (1977) Vulnerability-a new view of schizophrenia. J Abnorm Psychol 86:103-126.